Tue.Oct 29, 2024

article thumbnail

Heart Attack Patients Who Receive Heparin ASAP Are Better Primed for Cath Lab

Med Page Today

(MedPage Today) -- The heparin frequently given before percutaneous coronary intervention (PCI) should be pushed to as early as possible in patients with ST-segment elevation myocardial infarction (STEMI), according to findings from the Chinese.

article thumbnail

Swift intervention with early surgery aids elderly heart patients with aortic stenosis, finds study

Medical Xpress - Cardiology

Until now, patients with aortic stenosis—a narrowing of one of the heart's main valves—have had to wait until symptoms become severe before undergoing valve replacement. Findings from the EVOLVED study, however, indicate that patients can avoid symptoms such as chest pain, dizziness and fainting if surgery is performed at an earlier stage of the condition.

article thumbnail

Wegovy Cut Albuminuria by Half in Non-Diabetic CKD

Med Page Today

(MedPage Today) -- SAN DIEGO -- Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed. Among 101 patients, those who received 2.

article thumbnail

Early and Long-Term Colchicine After Acute Myocardial Infarction

American College of Cardiology

The goal of the CLEAR SYNERGY OASIS 9 trial was to determine the long-term cardiovascular (CV) effects of colchicine following percutaneous coronary intervention (PCI) for ST-segment elevation or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively).

article thumbnail

Cold Weather Heart Attacks; Preemptive Valve Procedures Flop; Better Bleeding Score

Med Page Today

(MedPage Today) -- A Chinese study suggested that cold weather may make people more susceptible to myocardial infarction with non-obstructive coronary arteries compared with myocardial infarction from obstructive disease. (European Heart Journal.

article thumbnail

Large-scale genetic study identifies targets that could reduce cardiovascular risk by modulating blood metabolites

Medical Xpress - Cardiology

A team of researchers have worked together to identify possible genes associated with certain metabolites—molecules involved in the body's biochemical processes—and cardiovascular risk.

article thumbnail

Yale New Haven Health names cardiac surgery chief

Becker's Hospital Review - Cardiology

Yale New Haven (Conn.) Health and the Yale School of Medicine have appointed Marc Pelletier, MD, division chief of cardiac surgery for the department of surgery and section chief of cardiac surgery at Yale New Haven Hospital as well as physician-in-chief of cardiac surgery for the health system's Heart and Vascular Center.

More Trending

article thumbnail

CLEAR SYNERGY, Co-STAR Add to Growing Body of Research Surrounding Colchicine Use

American College of Cardiology

Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, myocardial infarction, stroke or ischemia-driven revascularization.

article thumbnail

Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD

HCPLive

This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.

64
article thumbnail

Short- and long-term mortality in patients with type 2 diabetes after myocardial infarction– a nationwide registry study

Cardiovascular Diabetology

Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has i.

article thumbnail

Checking in on the Lung Health Cohort Trial

HCPLive

A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.

59
article thumbnail

25th Anniversary of a landmark study in coronary revascularization

Dr. S. Venkatesan MD

This study was released in NEJM without much fanfare at the fag end of the last century, (rather the millennium) in 1999. Dr. Bertram Pitt and his team scripted this from the Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA. One can’t expect even in your dreams a study like this would be be done in the future. This study tested PTCA vs with a single lipid lowering drug in terms of plaque regression.

article thumbnail

Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis

HCPLive

At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.

59
article thumbnail

Coronary Bioadaptor Systems Demonstrates Significant Improvement for Patients with ACS, Complex Lesion Subsets

DAIC

tim.hodson Tue, 10/29/2024 - 09:55 Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.

Stents 52
article thumbnail

Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis

HCPLive

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

64
article thumbnail

Impella ECP Study Demonstrates Safety, Efficacy for Use in High-Risk PCI

DAIC

tim.hodson Tue, 10/29/2024 - 11:29 Impella ECP pump insertion. Oct. 28, 2024 — Results from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference in Washington, D.C. Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and a global leader in heart recovery.

article thumbnail

SGLT2 Inhibitor Carry-Over Benefits Last How Long?

Med Page Today

(MedPage Today) -- SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During a median 2 years of post.

52
article thumbnail

Coronary Bioadaptor Systems Demonstrates Significant Improvement for Patients with Acute Coronary Syndrome, Complex Lesion Subsets

DAIC

tim.hodson Tue, 10/29/2024 - 09:55 Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.

Stents 52
article thumbnail

Real-time AI to Influence Clinical Decisions and Practice Towards Evidence-based Care: RAPIDxAI Trial

American College of Cardiology

In this interview, Drs. Allen Taylor and Derek Chew discuss the findings of the RAPIDxAI trial: re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting evidence to practice using AI.

article thumbnail

Randomized Controlled Trial on AI FFRangio Technology Presented at TCT

DAIC

tim.hodson Tue, 10/29/2024 - 10:14 Oct. 27, 2024 — Investigators from Gifu Heart Center and Fukuoka Sanno Hospital recently presented the results of the physician-initiated PROVISION 1 Study at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C. The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoi

article thumbnail

Systolic BP Polygenic Risk Score With Chlorthalidone Response

American College of Cardiology

What is the ability of a systolic blood pressure (SBP) polygenic risk score (PRS) to predict antihypertensive treatment (AHT) response and apparent treatment-resistant hypertension (aTRH)?

article thumbnail

Patients with Liver Disease Rarely Get Alcohol Use Disorder Pharmacotherapy

HCPLive

Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.

52
article thumbnail

PROTECTED TAVR: Post Hoc Analysis Suggests Possible Benefits of CEP During TAVR Based on Geographic Region

American College of Cardiology

While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based on geographic region.

TAVR 53
article thumbnail

Jordan Axelrad, MD, MPH: Addressing Nonadherence to IBD Therapies with Remote Monitoring

HCPLive

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

article thumbnail

Orbital Atherectomy vs. Conventional Balloon Angioplasty in Severely Calcified Coronary Arteries Prior to DES Implantation

American College of Cardiology

The goal of the ECLIPSE trial was to evaluate orbital atherectomy prior to drug-eluting stent (DES) implantation compared with conventional percutaneous coronary intervention (PCI) without atherectomy among patients with calcified coronary lesions.

article thumbnail

Kishore Iyer, MD, MBBS: Defining Short Bowel Syndrome, What Apraglutide Could Offer

HCPLive

Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.

52
article thumbnail

SIRONA: Sirolimus vs. Paclitaxel DCBS to Treat PAD

American College of Cardiology

Sirolimus-coated balloons were noninferior to paclitaxel-coated balloons in terms of safety and efficacy in treating patients with femoropopliteal artery disease, based on findings from the head-to-head.

Article 53
article thumbnail

Investing in women's heart health could save US $28B annually: 10 things to know

Becker's Hospital Review - Cardiology

"Discover how addressing women's heart health could lead to a $28 billion annual growth in the U.S. economy by 2040.

59
article thumbnail

ECLIPSE: Orbital Atherectomy vs. Conventional Balloon Angioplasty Prior to DES Implantation

American College of Cardiology

The routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions.

article thumbnail

Marlyn Mayo, MD: Elafibranor’s Safety, Efficacy in Patients with Advanced PBC

HCPLive

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

52
article thumbnail

Pooled Analysis From RHEIA and PARTNER 3 Compare TAVR vs. SAVR in Women

American College of Cardiology

In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.

TAVR 49
article thumbnail

Bruce Sands, MD: Long-Term Data for Mirikizumab in Ulcerative Colitis, Crohn’s Disease

HCPLive

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

52
article thumbnail

Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

American College of Cardiology

The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.

article thumbnail

Felzartamab Slows IgAN Decline in New Phase 2 Data

HCPLive

Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.

59
article thumbnail

Transcatheter aortic valve replacement in patients with systolic heart failure, aortic stenosis shows limited benefits

Medical Xpress - Cardiology

Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).

article thumbnail

Long and winding road to electrocardiographic imaging (ECGI)

HeartRhythm

The practice of medicine relies on noninvasive imaging modalities such as computed tomography or magnetic resonance imaging (MRI), which reconstruct noninvasively anatomy of internal organs. Electrocardiographic imaging (ECGI) performs functional imaging. It maps noninvasively the electrical function of the heart. It reconstructs electrical potentials, electrograms, activation sequences, and repolarization patterns on the epicardium.

Anatomy 45
article thumbnail

APPs, Gastroenterologists Struggle with PBC Diagnosis Strategy

HCPLive

A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.

52